Beigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 101,000 shares of Beigene stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $244.30, for a total transaction of $24,674,300.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
John Oyler also recently made the following trade(s):
- On Friday, March 7th, John Oyler sold 58,590 shares of Beigene stock. The shares were sold at an average price of $249.13, for a total transaction of $14,596,526.70.
Beigene Trading Down 3.9 %
ONC traded down $9.90 during trading hours on Friday, hitting $247.07. The company's stock had a trading volume of 662,352 shares, compared to its average volume of 459,760. Beigene, Ltd. has a 12 month low of $126.97 and a 12 month high of $287.88. The stock has a market capitalization of $24.18 billion, a PE ratio of -29.98, a P/E/G ratio of 7.73 and a beta of 0.65. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.
Beigene (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. Sell-side analysts expect that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on ONC shares. Macquarie lifted their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $207.00 to $320.00 in a research report on Monday, March 3rd.
View Our Latest Analysis on Beigene
About Beigene
(
Get Free Report)
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Featured Articles
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
